Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference

Rhea-AI Summary

Passage Bio, a clinical-stage genetic medicines company, will have CFO Simona King participate in a virtual panel at the 2022 Wedbush PacGrow Healthcare Conference on August 9, 2022, at 8:35 a.m. ET. The panel discussion, titled "Headspace - Updates in CNS Gene Therapy," will focus on advances in gene therapy for central nervous system disorders. A live webcast will be available on their website and a replay will be accessible for 30 days post-event. Passage Bio is dedicated to developing therapies for CNS diseases with limited treatment options, and is advancing three clinical programs in notable disorders.

PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Simona King, chief financial officer of Passage Bio, will participate in a virtual panel discussion at the upcoming 2022 Wedbush PacGrow Healthcare Virtual Conference being held from August 9-10, 2022.

Format: Panel Discussion
Title: Headspace - Updates in CNS Gene Therapy
Date: Tuesday, August 9, 2022
Time: 8:35 a.m. ET

A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.

About Passage Bio

Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing three clinical programs in GM1 gangliosidosis, Krabbe disease and frontotemporal dementia with several additional programs in preclinical development. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

For further information, please contact:

Passage Bio Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com

Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
MikeBeyer@sambrown.com

FAQ

What event is Passage Bio participating in on August 9, 2022?

Passage Bio is participating in the 2022 Wedbush PacGrow Healthcare Virtual Conference.

Who will represent Passage Bio at the 2022 Wedbush Conference?

Simona King, the CFO of Passage Bio, will represent the company.

What is the topic of the panel discussion at the conference?

The topic is "Headspace - Updates in CNS Gene Therapy."

What time is the Passage Bio panel scheduled for?

The panel is scheduled for August 9, 2022, at 8:35 a.m. ET.

Where can I watch the Passage Bio panel discussion?

The discussion can be watched live on Passage Bio's Investors & Media section of their website.

How long will the replay of the Passage Bio panel be available?

The replay will be available for 30 days following the event.

What diseases is Passage Bio focused on treating?

Passage Bio is focused on developing therapies for central nervous system disorders.

What clinical programs is Passage Bio advancing?

Passage Bio is advancing clinical programs in GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia.